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Abstract
DNA polymerase iota (polι) is a member of the Y-family, polymerases which are key
components in translesion synthesis (TLS). As part of the DNA damage response, TLS
allows cells to bypass damaged template DNA. Each member of the Y-family is capable
of accurately replicating across from certain lesions. All Y-family polymerases are
recruited by ubiquitination of the DNA sliding clamp, PCNA, by direct interaction with
PCNA and ubiquitin. The mechanism of polymerase choice is not well understood, nor are
the interactions between Ub-PCNA and the TLS polymerases. We studied the structure of
the complex between the interacting region of polι and Ub-PCNA. Polι appears to be unable
to bind all three monomers of homotrimeric Ub-PCNA simultaneously, even in a heavily
truncated form. The maximum complex ratio observed was two polymerases per UbPCNA ring. This assembly ratio limit may give insight into switching of multiple
polymerases at the PCNA platform in DNA damage response.
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Summary for Lay Audience
Accurate replication of DNA is a key biological process. Organisms have evolved
complementary maintenance processes to maintain the integrity of genetic information,
such as low-error replication machinery, damage repair mechanisms, and replacement
mechanisms using templates. These all work together to keep the mutation rate low.
Translesion synthesis (TLS) is one component of the damage-response process, but its role
is different. TLS replication tolerates damaged DNA and allows replication to continue
past lesions when repair processes cannot respond in time, at the risk of mutation. TLS
must be kept inactive to avoid unnecessary mutations, but quickly activated at damaged
sites. This is accomplished by modifying the major hub protein for replication processes, a
ring-shaped trimeric protein called PCNA. A small marker protein called ubiquitin (Ub) is
added to a specific site, which displaces the regular replication machinery and acts as a
binding site for the TLS proteins. The structure of the complex between Ub-PCNA and
TLS proteins is poorly understood. Each of the TLS polymerases handles different types
of damage well, but all of them are called by adding ubiquitin to PCNA. DNA polymerase
iota (polι), one of the TLS proteins, was chosen an example to investigate. After initial
attempts at structure determination by crystallography failed, indirect methods of probing
the complex were used. The stoichiometry of the complex was found to be limited to two
small polι constructs per UbPCNA ring by multiple independent methods. Coarse structural
determination was also attempted by small-angle X-ray scattering, with ambiguous results.
Here we argue that the limited stoichiometry observed and the unusual organization of polι
suggests that its role is that of a final attempt at lesion bypass when other TLS polymerases
have failed. This is in line with the minimal effect of having knocked out polι in model
organisms, and a reasonably safe role considering its high tendency to mutate and relatively
small number of lesions it appears to handle compared to the major TLS polymerase.
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1 Introduction
1.1 DNA Damage
In a living cell, DNA is constantly exposed to diverse forms of damage from both
external and internal sources. It is estimated that some form of DNA damage occurs over
10,000 times per day, per cell. Further complicating matters, DNA damage may take many
forms. These range in severity from the minor (abasic sites, adducts) to the potentially
catastrophic (double stranded breaks). Abasic sites are points where the nitrogenous base
has been removed while leaving the sugar-phosphate backbone intact, leaving an empty
space across from an unpaired base. Adducts are chemical additions to a correct base. Some
adducts are harmless and are added as part of genetic regulation, such as DNA methylation,
but other adducts are random occurrences. These random occurrences, especially if the
adducts are large or heavily distorting (such as the TT cyclobutane dimer caused by UV
radiation) are harmful to the cell, potentially producing a permanent mutation. Even minor
DNA damage can create distortions in the DNA double strand: the strand must twist and
adjust to accommodate the altered bases.
Cells have evolved a range of responses to DNA damage to maintain genome
stability, most famously the myriad repair mechanisms and pathways that lead to apoptosis
when the damage is too great. Many of these pathways are error-free. These responses are
not, however, appropriate in all situations the cell may encounter.

1.2 Translesion Synthesis
Translesion synthesis (TLS), a DNA damage tolerance mechanism, is an important
tool in the DNA damage response kit (Goodman and Woodgate, 2013). TLS fills a niche
in between damage repair and apoptosis, occurring during DNA replication. Ordinary
replicative polymerases (pols α, δ, and ε in humans) are characterized by high processivity,
restrictive active sites, and 3’-5’ exonuclease activity. The narrow active sites reduce the
probability of incorporating mismatched bases, and the exonuclease activity acts as
proofreading by removing mismatched bases. These features of replicative polymerases
are key to the high fidelity of replication but may also be a point of vulnerability for the
cell with DNA damage.
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DNA replication can be stalled at lesioned sites, which would be deadly to the cell
if not resolved (Durando et al., 2013). As noted above, lesioned sites disrupt the normal
shape of DNA bases and may distort the shape of the backbone strand around its site. These
changes make it difficult for replicative polymerases to replicate across lesions. It becomes
difficult to add a base across the lesion and increases the probability that the exonuclease
activity will remove an added base. The polymerase stalls at this site, but the helicase at
the replication fork decouples and continues to unwind the DNA. If the stalling is not
resolved, the increasing tracts of ssDNA will lead to a stress response that will eventually
activate apoptosis (Rodriguez et al., 2008). Error-free repair pathways tend to be slow and
may not be able to rescue replication in time. For this reason, evolution has selected for the
TLS pathway: a damage response that can act fast enough to rescue replication. TLS is
initiated by monoubiquitination of the proliferating cell nuclear antigen (PCNA) and
involves the displacement of the replicative polymerase and its replacement by a TLS
polymerase.

a

b

c

d

Figure 1.1 Translesion synthesis activation. Upon encountering a lesion, the replicative
complex stalls at the damage site (a). Stalling activates a stress response culminating in
ubiquitination of PCNA (b). Ubiquitination displaces the replicative polymerase and
recruits the TLS polymerase (c) which can then replicate past the damaged site (d).
TLS does come with risk: it is inherently error-prone and thus mutagenic (Yang et al.,
2018). Because of this danger, TLS must be tightly regulated (Ghosal and Chen, 2013).
TLS has also been found to be improperly active in cancer cells (Gao et al., 2016; MutterRottmayer et al., 2016). The most prominent family of TLS polymerases is the Y-family
(Vaisman and Woodgate, 2017).
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1.3 Y-family polymerases and Polι
Y-family polymerases resemble replicative polymerases but have key differences
to permit lesion bypass. These enzymes have low fidelity, low processivity, and low
catalytic efficiency when replicating across normal template DNA (Yang, 2014). The basic
Y-family organization contains a structured N-terminal catalytic domain and an
unstructured C-terminal regulatory domain. The catalytic domain is similar to the classical
polymerase structure, with the right-hand organization of a palm, finger, and thumb
domain.

Figure 1.2 Diagram of the classic polymerase domain (left) and the same superimposed
over a right hand for context (right). The finger domain (green) binds the incoming
nucleotide while the thumb domain helps to position the DNA strand. The palm domain
contains the active site.
The domain is differentiated by a looser active site, lack of exonuclease activity,
and the addition of a further domain known as the little finger (LF) domain. These
differences lead to an improved ability to accommodate and replicate across damaged
template DNA at the cost of fidelity. The C-terminal domain regulates the protein’s
activity. Though largely unstructured, they contain interacting motifs to that localize the
enzyme to ubiquitinated proliferating cell nuclear antigen (PCNA), the eukaryotic. The two
most important types of interacting motifs are the PCNA-interacting peptide (PIP or PIP
box) (Haracska et al., 2005) and motifs for binding ubiquitin. The PIP-box of Y-family
polymerases are non-canonical (Haracska et al., 2005) and have less affinity for PCNA
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relative to replicative polymerases. There are two classes of motifs for ubiquitin binding:
the ubiquitin binding zinc finger (UBZ) and the ubiquitin-binding motif (UBM). Together,
these binding motifs lead to strong affinity for Ub-PCNA but poor affinity to PCNA in
general. This keeps Y-family activity at a minimum under normal conditions but rapidly
recruits them to stalled replication forks after PCNA ubiquitination. Y-family polymerases
are themselves able to be ubiquitinated, and it is hypothesized that this ubiquitination
prevents them from activating by keeping them in a self-binding conformation to preclude
them from binding to Ub-PCNA (McIntyre et al., 2013).
There are four members of the Y-family polymerases, each with different activities.

Figure 1.3 Comparison of Y-family polymerases. N-terminal catalytic domain
organization is conserved across all members of the family, with classic polymerase core
in red and the little finger domain in red. The C-terminal regulatory domain shows
significant differences in composition and organization (adapted from Yang and
Woodgate, 2007).
Each polymerase displays different catalytic properties and play unique
roles. Rev1 is an unusual case: its catalytic activity is limited to adding dC across from any
template, and it itself serves as a scaffold protein for further responses. Polη is the best
studied member of the family. Humans lacking polη activity are afflicted with a variant of
xeroderma pigmentosum (XPV), a skin disease which is characterized by high sensitivity
to UV light. This is caused by losing polη’s ability to bypass TT cyclobutane dimers
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quickly and accurately (Masutani et al., 1999), which is a function that other TLS
polymerases lack. Polη also has a role in promoting monoubiquitination of PCNA at K164
(Durando et al., 2013). Polκ’s primary function is strand extension following lesion bypass
(Jha and Ling, 2018; Lone et al., 2007), but it is also capable of bypassing lesions on its
own. Polι’s role in TLS is poorly understood. Its activity largely overlaps with that of polη,
and likely functions as a backup or complement polymerase, such as its activity in XPV
organisms (Wang et al., 2007) and its accurate bypass of 8-oxo-guanine lesions (Kirouac
and Ling, 2011). One of its notable qualities is its unusual mutation spectrum: polι
replicates inaccurately over a template T and favours misincorporation of dC over dA by a
factor of 3:1. Despite its inaccuracy, polι has been shown to play a role in maintaining
genetic integrity (Iguchi et al., 2014). The structure of its catalytic domain (PDB code:
1T3N) has been solved in complex with various substrates (Nair et al., 2004).
Pol follows the basic Y-family organization, and its regulatory domain contains a
PIP-box and two UBMs. The UBM binds to ubiquitin in an unorthodox manner and does
not bind to the typical isoleucine-44, rather the nearby isoleucine-8 (Bomar et al., 2010).
The binding is also stabilized by electrostatic contacts (Burschowsky et al., 2011).
Polι is a useful model for studying the Y-family polymerase family’s behaviour in
vitro. Full-length Y-family proteins tend to be difficult to overexpress and purify in
significant quantities, but the catalytic domain and regulatory domain may be individually
soluble. The PIP-box of polι is located between the two domains, so that proteins of each
domain can be created which contain the PIP-box in its natural point in the structure. This
permits independent study of the N-terminal and C-terminal domains in proper complex
with its key binding partner and regulator, PCNA.
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1.4 PCNA and the Regulation of TLS
Human proliferating cell nuclear antigen (PCNA) is a key hub that physically
bridges DNA and a multitude of proteins that act on DNA. PCNAs are the eukaryotic
analogue to the bacterial β clamp. In humans, the protein naturally forms a ring-shaped
homotrimer which can be loaded onto DNA and slide along the strand. The angle of the
basic patches matches that of the backbone and contributes to the “cogwheel”-type sliding
(De March et al., 2017). PCNA does not have enzymatic activity; rather it is a platform for
a wide range of proteins.

Figure 1.4 Diagram of the structure of PCNA. PCNA is a ring- shaped homotrimer. Each
unit is composed of two similar domains, between which is a hydrophobic pocket and an
unstructured region called the inter-domain connecting loop (IDCL, shown in black). The
overall appearance is a ring with pseudo-sixfold rotational symmetry. The central pore is
lined with basic residues which form weak interactions with the DNA backbone, permitting
its sliding action (March and Biasio, 2017).
The hydrophobic pocket and IDCL features form a binding site for the PIP box, which is a
common binding motif in proteins which interact with DNA. The crystal structure of the
polι PIP-box in complex with Ub-PCNA is known (Hishiki et al., 2009). The PIP binding
site sits on the forward face of the ring, in the direction of the sliding. The angle of the
basic patches matches that of the backbone and contributes to the “cogwheel”-type sliding
(De March et al., 2017). PCNA does not have enzymatic activity; rather it is a platform for
a wide range of proteins.
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In addition to the PIP-binding site, PCNA is subject to varied modifications to
recruit specific proteins under specific circumstances. PCNA has been found to be
SUMOylated, ISGylated, and ubiquitinated, all at multiple possible sites (Chen et al.,
2011). Each modification signals for different responses, so PCNA acts as both the
interface between DNA and its proteins and the central point of regulation for many DNArelated processes.

Figure 1.5 Regulation of DNA damage responses by modification of human PCNA.
Monoubiquitination of K164 is the signal that recruits translesion polymerases, including
Y-family polymerases, to stalled replication forks to bypass lesions (adapted from Chen et
al., 2011).
Stalled replication leads to monoubiquitination of PCNA at lysine-164 by RAD18,
which activates the TLS response. This dislodges the replicative polymerase and recruits
TLS polymerases, including polι. The exact mechanism is unknown, as is the structure of
7

the active TLS complex. All TLS enzymes are recruited by this same signal, which
introduces a polymerase-selection problem: how can a cell ensure that a given lesion is
bypassed by the most suitable polymerase? There are two competing models for this
complex: the tool-belt model (Boehm et al., 2016) and the polymerase-switch model
(Dovrat et al., 2014).
The tool-belt model is based on the homotrimeric structure of PCNA. Since PCNA
(and Ub-PCNA) has threefold rotational symmetry, the system effectively contains 3 sets
of identical binding sites. The active complex is hypothesized to be able to host a set of
TLS polymerases (for example, pols η, ι, and κ) and rotate around the DNA to allow each
polymerase to interrogate the lesion. In this way, the most suitable polymerase is the most
likely to bypass the lesion and resolve the stalling.
The polymerase-switch model is not mutually exclusive with the tool-belt model,
but it may occur without the creation of tool belts. In this model, only a single polymerase
binds to Ub-PCNA at any time, requiring a complete detachment and new binding event to
change the polymerase that is acting on DNA. Polymerases that bind to Ub-PCNA are
themselves ubiquitinated while bound. Should the polymerase detach (a common
occurrence since Y-family polymerases are distributive enzymes, with low processivity),
it reverts to its self-binding closed conformation and is prevented from rebinding to UbPCNA. Like the tool-belt model, this model resolves the polymerase-selection problem by
decreasing the probability that the lesion will be bypassed by a polymerase which does not
easily act upon the lesion. Though this is perfectly compatible with a tool-belt system (since
there are more than three TLS polymerases, it would be necessary for that model to
function), this model does not require in vivo tool belts to function and is compatible with
a system using one bound polymerase at a time.

1.5 Outline of Investigation
This project set out to investigate the structure of the complex between polι’s
regulatory domain and Ub-PCNA. Determination of the crystal structure of the complex
between Ub-PCNA and polι may offer clues about the mechanism of TLS and the
behaviour of the lesion bypass complex.
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Separate proteins of polι and (Ub-)PCNA and fusion proteins of two proteins had
been developed for crystallization trials. After crystallization trials were exhausted, the
unfused complex was examined to determine whether the complex was forming as
hypothesized. Initial findings in multiangle light scattering experiments, followed by
analytical ultracentrifugation and small-angle X-ray scattering studies, showed that the
complex composition was not the expected 3:1 polymerase:trimer. Instead, the highest
stoichiometry ever observed was 2:1 polymerase:trimer. Small-angle X-ray scattering
experiments were performed to create a low-resolution structure in solution.

2 Materials and Methods
The following lists of materials were used in experiments. In certain procedures the
standard buffer may not be used; in this case the modification may be noted in the section
describing the method in question.

2.1 Bacterial strains and plasmids
Escherichia coli was the organism of choice for cloning procedures and protein
production. The following strains were used in this project.
Table 2.1 List of bacterial strains used in the study.
Strain Name

BL21-DE3
(pRARE)

Use
Protein
Production
Protein
Production

DH5α

Cloning

BL21-DE3

Key Features
Protease deficient, primary protein production
strain (Novagen)
Protease deficient, pRARE plasmid requires
chloramphenicol selection (Novagen)
High transformation efficiency
(Thermo Fisher Scientific)

The following plasmids were used as vectors for protein expression. Each plasmid
is IPTG-inducible, encoded an N-terminal solubility tag and contained an antibiotic
resistance for selection. The solubility tag is cleavable by TEV protease. The exception to
the tagging system is the pET3a plasmid, which encodes a C-terminal 6xHis tag which is
not cleavable. This vector was used for a single ubiquitination enzyme.
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The pRARE plasmid was not transformed into bacteria at the same time as the vector
plasmid; rather it was included in the competent cells. The plasmid encodes tRNAs that are
rarely used in E. coli but common in other organisms. The extra tRNAs produced help to
increase protein yield by removing the scarcity as a bottleneck. It is included on this list
for the sake of completeness and to note the antibiotic required to select for its inclusion.
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2.2 List of Standard Buffers
Each buffer listed with its formulation and its main use. In cases where an experimental
protocol uses a modified buffer, the modification is listed in its Methods section.
Table 2.2 Standard buffers used in the study.
Buffer Name
His-Binding Buffer
MBP-Binding
Buffer
Dialysis Buffer
Tandem Loading
Buffer
Q Buffer A
Q Buffer B
Heparin Buffer C
Heparin Buffer D
Sizing Buffer
SAXS Buffer

Use
Ni Affinity
Chromatography
Amylose Affinity
Chromatography
Overnight
removal of
imidazole
1-step 2nd Ni
affinity and Q
column loading
Anion Exchange
Chromatography
Anion Exchange
Chromatography
Heparin Affinity
Chromatography
Heparin Affinity
Chromatography
Standard
Experimental
Buffer
SEC-SAXS
running buffer

Components
50 mM Tris pH 7.5, 500 mM NaCl, 5%
glycerol (v/v)
20 mM Tris pH 7.5, 200 mM NaCl, 1 mM
EDTA
25 mM Tris pH 7.5, 200 mM NaCl, 5%
glycerol (v/v)
25 mM Tris pH 7.5, 150 mM NaCl, 5%
glycerol (v/v)
25 mM Tris pH 7.5, 2.5% Glycerol, 1 mM
EDTA
25 mM Tris pH 7.5, 1 M NaCl, 2.5% glycerol
(v/v), 1 mM EDTA
50 mM sodium acetate (NaAc) pH 5.5, 5%
glycerol
50 mM NaAc pH 5.5, 1 M NaCl, 5% glycerol
(v/v)
20 mM Tris pH 7.5, 150 mM NaCl
20 mM Tris pH 7.5, 150 mM NaCl, 2.5%
glycerol (v/v)
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2.4 Expression and purification
The protein complex of interest is composed of UbPCNA and polι. UbPCNA is
created by enzymatically ubiquitinating purified PCNA in vitro. Full-length polι cannot
be expressed in soluble form, so truncated forms of the C-terminal were created. Fusion
proteins featuring linked PCNA and polι were also created for crystallization purposes.

Figure 2.1 Schematic of polι proteins used in study. Segments of the polι C-terminal region
(green) were expressed and purified, both as individual proteins and as fusion constructs
with PCNA (blue). Fusion constructs are connected by flexible linkers. The PIP-UBM1
protein is the narrowest segment of polι used, including the PIP box (yellow) and UBM1
(orange). The LF constructs include the little finger (LF) domain at the N-terminal. PIPUBM1-UBM2 constructs include the full C-terminal domain and all interacting regions of
interest.
2.4.1 PIPUBM1-PCNA Fusion Protein Purification
Fusion proteins were developed to express the polι-PCNA complex as a single unit
to eliminate the need for excess PIP-UBM1 to saturate the PCNA ring and to simplify the
production process. The C-terminus of the PIP-UBM1 protein was fused to the N-terminus
of PCNA by a flexible linker. The linker must be flexible and long enough to permit the
desired interactions. It must also be polar to stabilize solvent interactions (Chen et al.,
2013).
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Table 2.3 Polι-PCNA fusion proteins used in this study.
Protein Name
PIP-UBM1-PCNA

PIP-del26-PIP-PCNA

PIP-del36-PIP-PCNA

PIP-del46-PIP-PCNA

LF-PIP-UBM1-PCNA

StrpII-PIP-UBM1PCNA

StrpII- PIP-del26-PIPPCNA

StrpII- PIP-del36-PIPPCNA

StrpII- PIP-del46-PIPPCNA

Description
Fusion between polι 415-530 and PCNA N-terminus, linked
by a 24aa flexible linker. Purified using TEV-cleavable Nterminal His-Mocr tag.
Fusion between polι 415-530 ΔK439-464 and PCNA Nterminus, linked by a 24aa flexible linker. Purified using TEVcleavable N-terminal His-Mocr tag.
Fusion between polι 415-530 ΔK439-474 and PCNA Nterminus, linked by a 24aa flexible linker. Purified using TEVcleavable N-terminal His-Mocr tag.
Fusion between polι 415-530 ΔK439-474, ΔK484-493 and
PCNA N-terminus, linked by a 24aa flexible linker. Purified
using TEV-cleavable N-terminal His-Mocr tag.
Fusion between polι 415-530 and PCNA N-terminus, linked
by a 24aa flexible linker. Purified using TEV-cleavable Nterminal His-Mocr tag.
Fusion between polι 415-530 and PCNA N-terminus, linked
by a 24aa flexible linker. Purified using TEV-cleavable Nterminal His-Mocr tag. Strep-II tag is inserted after the tag
such that it is the N-terminal of the cleaved protein
Fusion between polι 415-530 ΔK439-464 and PCNA Nterminus, linked by a 24aa flexible linker. Purified using TEVcleavable N-terminal His-Mocr tag. Strep-II tag is inserted
after the tag such that it is the N-terminal of the cleaved protein
Fusion between polι 415-530 ΔK439-474 and PCNA Nterminus, linked by a 24aa flexible linker. Purified using TEVcleavable N-terminal His-Mocr tag. Strep-II tag is inserted
after the tag such that it is the N-terminal of the cleaved protein
Fusion between polι 415-530 ΔK439-474, ΔK484-493 and
PCNA N-terminus, linked by a 24aa flexible linker. Purified
using TEV-cleavable N-terminal His-Mocr tag. Strep-II tag is
inserted after the tag such that it is the N-terminal of the
cleaved protein
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Fusion proteins were developed to express the polι-PCNA complex as a single unit
to eliminate the need for excess PIP-UBM1 to saturate the PCNA ring and to simplify the
production process. The C-terminus of the PIP-UBM1 protein was fused to the N-terminus
of PCNA by a flexible linker (see Figure 2.1). The linker must be flexible and long enough
to permit the desired interactions. It must also be polar to stabilize solvent interactions
(Chen et al., 2013).
The StrpII tag (Schmidt and Skerra, 2007), originally designed as an affinity tag,
was added to the N-terminal of the cleaved protein. The tag was originally considered to
stabilize the N-terminus of the protein and eliminate a possible degradation product, but it
was ultimately included to alter the crystallization behaviour and open a new round of
screening (Lukat et al., 2008)
All fusion proteins were expressed in E. coli BL21 (DE3) cells. Cells are grown in
lysogeny broth (LB) + Ampicillin (100 mg/L) at 37 ºC to OD600= 0.6 and then induced
with 0.5 mM IPTG. PIP-UBM1 fusions are expressed at 37 ºC and harvested 4 hours after
induction. LF-PIP-UBM1 fusions are expressed at 16 ºC and grown overnight before
harvest. Cells are pelleted and stored frozen at -80ºC.
Cell pellet from 1 L culture was thawed in a room temperature water bath at use
and resuspended in a lysis buffer made from His-binding buffer with 1 mM benzamidine,
1 mM PMSF, and 5 mM BME. Cells were lysed using a homogenizer and the crude lysate
was centrifuged at 20,000 rpm (approximately 40,000 g) for 30 minutes. The supernatant
was poured off and loaded on a 5mL Roche His cOmplete Ni column. The column was
washed with 50mL His-binding buffer, 50mL of His-binding buffer adjusted to 1 M NaCl,
50 mL His-binding buffer, and finally 50 mL of His-binding buffer with 10 mM imidazole.
The column was then eluted using His-binding buffer with 500 mM imidazole into 12x1.5
mL fractions. Fractions were pooled based on spot test and TEV protease was added at a
ratio of 1 mg for every 30 mg of protein in the pooled fractions. The pooled sample was
dialyzed against 150mM NaCl, 25 mM Tris pH 7.5, and 5% glycerol at 4 ºC overnight.
The digested sample was retrieved the next morning and loaded onto a tandemly
connected Roche nickel column flowing into a 5 mL GE HiTrap Q column equilibrated to
150 mM NaCl. The digested sample was pushed through the column with additional buffer
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and the Q column was removed, then connected to an AKTA Purifier for elution. The
protein was eluted using a gradient of 15-70% buffer B over 7.5 CV and collected in 1.5
mL fractions based on UV absorbance. A contaminant band produced a pronounced
shoulder in the peak, but the contaminant could be reasonably eliminated by pooling early
fractions only. The early fractions were pooled and concentrated to 10mg/mL and were
used to set up crystallization trays.
2.4.2 polι C-terminal Protein Purifications
Note on buffers: PIP-UBM1 proteins are purified in standard buffers at pH 8.7 to
allow binding to Q column. Q buffer B contains 500 mM NaCl to make low-salt buffers
more accurately.
E. coli BL21 (DE3) cells expressing 8xHis-PCNA were grown in LB + Ampicillin
(100 mg/L) to OD600 = 0.7 at 37 ºC and induced with 0.5 mM imidazole. Cells were grown
a further four hours at 37 ºC before harvest. Cell pellets were stored at -80 ºC.
Table 2.4 Polι C-terminal proteins used in the study.
Protein Name
PIP-UBM1
PIP-UBM1 del 26

PIP-UBM1 del 36

LF-PIP-UBM1
PIP-UBM1UBM2

Description
Main polι C-terminal protein, containing aa 415-530. Purified using
TEV-cleavable N-terminal HisMocr or HisMBP tags.
Truncated polι C-terminal protein, containing aa 415-530 ΔK439464. Purified using TEV-cleavable N-terminal HisMocr or
HisMBP tags.
Truncated polι C-terminal protein, containing aa 415-530 ΔK439474. Purified using TEV-cleavable N-terminal HisMocr or
HisMBP tags.
polι C-terminal protein with little finger polymerase domain (LF),
containing aa 415-530. Purified using TEV-cleavable N-terminal
HisMocr or HisMBP tags.
Full polι C-terminal protein, containing aa 415-715. Purified using
TEV-cleavable N-terminal HisMocr or HisMBP tags.

Cell pellet from 1 L culture was thawed in a room temperature water bath at use
and resuspended in a lysis buffer made from His-binding buffer with 1 mM benzamidine,
1 mM PMSF, and 5 mM BME. Cells were lysed using a homogenizer and the crude lysate
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was centrifuged at 20,000rpm for 30 minutes. The supernatant was then loaded on a 5mL
Roche His cOmplete Ni column.
The Ni column was washed with 150 mL of His-binding buffer and then eluted into
12x1.5 mL fractions using His-binding buffer with 500 mM imidazole. Fractions were
pooled based on spot test and TEV protease was added at a ratio of 1 mg for every 20 mg
of protein and dialyzed overnight against 20 mM Tris-HCl pH 8.7, 200 mM imidazole,
2.5% glycerol, and 5mM BME.
The digested protein was retrieved the next morning and diluted 6x in buffer A. The
diluted protein was loaded on a 5mL HiTrap Q column equilibrated in 6% buffer B (30
mM NaCl). The protein was eluted on an AKTA Purifier from the column using a gradient
of 6%-50% over 6 column volumes and collected in 1.5 mL fractions based on UV
absorbance. Protein was concentrated to 15 mg/mL, spiked to 20% glycerol (v/v), and flash
frozen before storage at -80 ºC.
2.4.3 PCNA Purification – Primary Method using His-tagged protein
E. coli BL21 (DE3) cells expressing 8xHis-PCNA were grown in LB + Ampicillin
(100 mg/L) to OD600 = 0.7 at 37 ºC and induced with 0.5mM imidazole. Cells were grown
a further three hours at 37 ºC before harvest. Cell pellets were stored at -80 ºC.
Cell pellet from 1 L culture was thawed in a room temperature water bath at use
and resuspended in a lysis buffer made from His-binding buffer with 1 mM benzamidine,
1 mM PMSF, and 5 mM BME. Cells were lysed using a homogenizer and the crude lysate
was centrifuged at 20,000rpm for 30 minutes. The supernatant was then loaded on a 10mL
Roche His cOmplete Ni column.
The column was then eluted using His-binding buffer with 500 mM imidazole into
16x1.5 mL fractions. Fractions were pooled based on spot test and TEV protease was added
at a ratio of 1 mg for every 40 mg of protein in the pooled fractions. The pooled sample
was dialyzed against 200 mM NaCl, 25 mM Tris pH 7.5, and 5% glycerol at 4ºC overnight.
Protein sample was retrieved the next morning and spiked to 500mM NaCl. The
sample was passed through His cOmplete column again and the flowthrough collected.
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Flowthrough was diluted with Q buffer A to 150 mM NaCl and loaded on 10 mL Q column
pre-equilibrated in 15% B. Column was eluted using a gradient of 15-70% B over 7.5 CV
and collected in 1.5 mL fractions based on UV absorbance. Peak fractions were pooled and
concentrated to roughly 10 mg/mL, spiked to 20% glycerol and flash-frozen before storage
at -80 ºC.
2.4.4 PCNA purification – Method for untagged PCNA
Untagged PCNA was at first the only PCNA protein available, before HisPCNA
that was TEV-cleavable was designed. A small number of standard PCNA purifications
were performed using this method. The main use of this purification was to produce lysine
to arginine (K/R) mutant PCNA for ubiquitination tests (outlined below).
Table 2.5 Untagged PCNA proteins purified by ion exchange/heparin affinity method.
Protein Name

Description

PCNA

Human PCNA, untagged

PCNA K164R

Untagged human PCNA with K164R point mutation

PCNA K168R

Untagged human PCNA with K168R point mutation

PCNA K164/168R

Untagged human PCNA with K164/168R point
mutations

E. coli BL21 (DE3) cells expressing human ubiquitin (Ub) were grown in LB +
Ampicillin (100 mg/L) at 37 ºC to OD600 = 0.7 and then induced with 0.5mM IPTG. After
induction cells were incubated at 37ºC for 3 hours and harvested (normal yield 3.5-4 g/L),
and the cell pellets were stored at -80ºC.
Purification began by thawing 1 L worth of cells (3.5-4 g) and suspending in 15%
Buffer B with 5 mM BME, 0.01% (v/v) NP-40, and 1 mM each benzamidine and PMSF.
The suspended cells were then lysed using a homogenizer. The lysate was spun down at
20,000 rpm for 30 minutes at 4 ºC. The supernatant was poured off and then loaded on a
pre-equilibrated Q column. The Q column was then connected to the purifier and eluted
using a 15-25% gradient over 10 mL, followed by 25-70% over 40mL. The initial slow
gradient removes a strong band of protein and DNA immediately before the elution of the
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PCNA. Fractions with a conductivity between 20 mS and 40 mS were examined by SDSPAGE and relatively clean fractions were pooled and dialyzed overnight against 10%
buffer D to prepare for heparin chromatography the next day.
Protein was loaded on a pre-equilibrated heparin column and then connected to the
purifier. The column was eluted using a 10-50% gradient over 40 mL. Peak fractions were
pooled and diluted back to 10% D for reloading. The reloaded protein was then eluted using
a 10-70% gradient and peak fractions were concentrated for storage, typically 10 mg/mL.
Protein was flash frozen and stored at -80 ºC.
2.4.5 Ubiquitin Purification
E. coli BL21 (DE3) cells expressing human ubiquitin (Ub) were grown in LB +
Ampicillin (100 mg/L) at 37 ºC to OD600 = 0.7 and then induced with 0.5mM IPTG. After
induction cells were incubated at 30ºC overnight and harvested, and the cell pellets were
stored at -80ºC.
Full scale purification requires 4 L worth of cells to begin. Cells were thawed using
a room-temperature water bath and resuspended in Buffer A (50mM NaAc pH 4.5, 1mM
EDTA) and lysed using a homogenizer. The lysate was spun down at 20,000 rpm for 30
min at 4 ºC. The supernatant was collected and heated in a water bath set to 75ºC for 30
minutes. The sample was shaken every 3 minutes during this period to heat evenly. The
heat-treated sample was then centrifuged as above, and the supernatant was collected. The
supernatant was collected, and its pH was brought to 7.5 using 1M Tris-HCl pH 8 and
loaded on a 10mL Q column equilibrated in 5% buffer A and the flowthrough collected.
The Q column was cleared using 2M NaCl and the collected flowthrough was reloaded
onto the column. This second flowthrough was collected and concentrated using a pressurepowered concentrator to 10mL and then concentrated to 19mg/mL using a centrifugal
concentrator. The protein was aliquoted and flash-frozen before storage at -80 ºC.
2.4.6 hUba1 Purification
E. coli BL21 (DE3) cells expressing His-hUba1 were grown in LB + Ampicillin
(100 mg/L) at 37 ºC to OD600 = 0.7, and then induced with 0.25 mM IPTG. Cells were then
grown overnight at 16 ºC and then harvested. Cell pellets were stored at -80 ºC.
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Cells from 2 L of culture were thawed and resuspended in His-binding buffer with
benzamidine and PMSF. Cells were lysed on homogenizer and spun down at 20,000 rpm.
The supernatant was loaded on a 10 mL Roche His cOmplete Ni column and washed with
200 mL buffer and 100 mL buffer with 10 mM imidazole. The protein was eluted into
16x1.5 mL fractions with His-binding buffer + 500 mM imidazole. The fractions
containing protein were pooled and diluted 10x in Q buffer A to 50 mM NaCl and loaded
onto a 10 mL Q column. The Q column was eluted on an AKTA Purifier using a gradient
of 5%-50% over 10 CV and collected in 1.5 mL fractions based on UV absorbance. Peak
fractions were pooled and concentrated to 3.8 mg/mL. Aliquoted protein and flash-froze
before storing at -80 ºC.
2.4.7 hUbC S22R Purification
E. coli BL21 (DE3-pRARE) cells expressing His-hUba1 S22R were grown in LB
+ Kanamycin (50 mg/L) + Chloromphenicol (34 mg/L) at 37 ºC to OD600 = 0.7 and then
induced with 0.5 mM IPTG. Cells were grown at 16ºC overnight and harvested. Cell pellets
were stored at -80ºC.
Cells from 2 L of culture were thawed and resuspended in His-binding buffer with
benzamidine and PMSF and then lysed on a homogenizer. The lysed cells were centrifuged
at 20,000 rpm for 30 minutes and the supernatant was then loaded onto a 10 mL Roche His
cOmplete Ni column. The column was then washed with 100 mL His-binding buffer,
followed by 50 mL of His-binding buffer with 10 mM imidazole. The protein was eluted
into 16x1.5 mL fractions with His-binding buffer with 300 mM imidazole. Fractions with
protein were pooled and digested with 1 mg TEV protease for every 20 mg protein while
dialyzing against 25 mM Tris pH 7.5, 200 mM NaCl and 5% glycerol overnight. The next
morning the digested protein was spiked to 500 mM NaCl and 10 mM MgCl2 before being
loaded on a 10 mL Ni column. The flowthrough was collected and concentrated to 17.2
mg/mL, flash frozen, and stored at -80 ºC.

19

2.5 Ubiquitination of PCNA
2.5.1 Ubiquitination Reaction Conditions
Reliable, site-specific monoubiquitination of PCNA at K164 was necessary for the
study. The PCNA ubiquitination reaction was performed under the following conditions in
aqueous buffer, modified from a previously published condition (Hibbert and Sixma,
2012). A typical ubiquitination reaction has a PCNA concentration of ~0.5 mg/mL. As a
matter of good practice, protein concentrations were re-evaluated after new stocks of Uba1,
UbC, and/or ubiquitin were prepared.
Table 2.6 Ubiquitination reaction conditions.
Component

Concentration

MMT Buffer 10x pH 9

1x

NaCl

25 mM

MgCl2

3 mM

TCEP

0.5 mM

ATP pH 7

3 mM

PCNA

16 μM

Ubiquitin

22 μM

Uba1

40 nM

UbC S22R

16 μM

Note: MMT 10x buffer is a broad-range buffer mixture that is 200 mM malic acid, 400 mM
MES, and 400 mM Tris.
The final reaction buffer volume was calculated from the total mass of PCNA to be
ubiquitinated. All non-protein components were mixed first at room temperature, and then
each protein was added individually with mixings in between. The final component added
was hUbiquitin. The reaction mixture was incubated in a water bath at 37 ºC for 80 minutes,
with gentle mixing performed every 20 minutes. At the end of the reaction time, the
reaction mixture was loaded on an appropriately sized HiTrap Q column pre-equilibrated
with 15% Buffer B and washed with 2 CV of the equilibration buffer. The column was then

20

eluted on an AKTA Purifier using a gradient of 15%-70% over 4 CV and collected in 1.5
mL fractions based on UV absorbance.
2.5.2 Confirmation of ubiquitination specificity by Mass Spectrometry
Polι specifically binds to PCNA ubiquitinated at lysine-164 (K164), so it was
important to confirm that the ubiquitination reaction used was only ubiquitinating at this
specific residue. Mass spectrometry was used to determine the ubiquitination site(s) present
(Parker et al., 2009).
Freshly ubiquitinated Ub-PCNA from a small-scale ubiquitination was run on an
SDS-PAGE gel. The ubiquitination reaction was run for two hours rather than the usual 80
minutes to improve the chances of multiple ubiquitinations. A gel was run using multiple
concentrations of the same sample across all the lanes to provide options for resolution vs.
sample size. Spots were cut from the gel using a robotic sampler and submitted for trypsin
digestion. The peptide products of the digest were submitted for MALDI-TOF to measure
the masses of the fragments.

a

b

c

Figure 2.2 Workflow for ubiquitination site determination by mass spectrometry.
Ubiquitinated protein (a) is digested in-gel to peptides (b), including a small GG isopeptide
scar on the ubiquitination site(s). The masses of the peptides are determined by MALDITOF mass spectrometry (c).
Observed peptides were compared to a generated library of possible tryptic
digestion products (including possible missed cutting sites, oxidation products, and non21

specific modifications) from Ub-PCNA to identify fragments containing a mass shift of
+129 Da from the normal mass, which corresponds to the GG scar from the ubiquitin-lysine
isopeptide bond. Fragments marked with this scar are identified as ubiquitination sites.
2.5.3 Confirmation of ubiquitination specificity using mutant PCNA
The specificity of the ubiquitination reaction was also tested by performing the
normal ubiquitination reaction (see above) using K/R mutants of PCNA. Arginine is a
positively charged amino acid with a long side chain like lysine, but it cannot be
ubiquitinated like lysine (Hibbert and Sixma, 2012). Such mutations, properly placed,
should abolish ubiquitination without affecting other properties of the protein.
Three PCNA mutants were generated by point mutation and purified using the
untagged PCNA purification procedure: K164R, K168R, and K164/168R. K164 is the
target site, and K168 was believed to be the most probable off-target site based on its
proximity to the target site. A ubiquitination reaction was performed on each mutant and a
wild-type control in parallel. The start and end points of the reaction were run on an SDSPAGE gel to determine which of the mutants were able to be ubiquitinated under these
conditions.
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2.6 Crystallization Trials
PIP-UBM1-PCNA fusion proteins were screened for possible crystallization
conditions using the following kits:
Table 2.7 Crystal screening kits used.
Crystal Kit

# of Wells

PEG Smear

96

Wizard 1-4
Natrix 1+2

192
96

PEG 400 Ion

48

PEG 550
MME Ion
PEG 1000 Ion
PEG 1500 Ion
PEG 2000 Ion
PEG 2000
MME Ion
PEG 4000 Ion
PEG 5000 Ion
PEG 6000 Ion

Manufacturer
Mixed in house, based on
(Chaikuad et al., 2015)
Molecular Dimensions
Hampton (Scott et al., 1995)
Hampton (Mcpherson,
2001)

48

Hampton

48
48
48

Hampton
Hampton
Hampton

48

Hampton

48
48
48

Hampton
Hampton
Hampton
Molecular Dimensions
(Gorrec, 2009)
Hampton (D’Arcy et al.,
2003)
Molecular Dimensions
(Newman et al., 2005)

Type
PEG mixtures, salts
Broad Screen
Salt mixture
PEG 400 and salts
PEG 550 monomethyl
ether and salts
PEG 1000 and salts
PEG 1500 and salts
PEG 2000 and salts
PEG 2000 monomethyl
ether and salts
PEG 4000 and salts
PEG 5000 and salts
PEG 6000 and salts
Broad, includes ligands,
cryoprotective

Morpheus

96

Index

96

JCSG+

96

MIDAS

96

Molecular Dimensions

Narrow salt/pH, unusual
polymeric precipitants

Protein
Complex

96

Qiagen

PEG and salt screen

PACT Premier

96

Screens pH, cations, and
anions

Crystal Screen
1+2

96

Molecular Dimensions
(Newman et al., 2005)
Hampton (Jancarik and
Kim, 1991)
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Broad screen, diagnostic
Broad

Broad

Fusion proteins were screened after concentrating ion exchange fractions, either
from purification or after ion exchange refresh from storage at -80 ºC. Protein was
concentrated to 10-15 mg/mL and diluted as needed before setting up trays. Trays were
placed in incubators set to 18 ºC and observed over a few months for crystals using a
microscope.
Screening proceeded using 1+1 µL drops using protein concentrations of 5 or 10
mg/mL. Two basic screening setups were used. First; hanging drop vapour diffusion
experiments were set up in 24-well plates using a precipitant solution mixed in the drop
and a well condition of 0.5 mL of 1M (NH4)2SO4 or 1.5M NaCl. Second; sitting drop
experiments were performed using a well condition of 80 µL of the precipitating condition.

2.7 Size-Exclusion Chromatography – Multi-Angle Light Scattering (SEC-MALS)
2.7.1 Sample Preparation for SEC-MALS
Ub-PCNA and PIP-UBM1 were taken out of -80 ºC storage and thawed. Both
proteins were refreshed by injecting on S200 equilibrated in sizing buffer + 0.5 mM DTT.
Peak fractions of each were pooled to create high quality samples of sufficient
concentration directly from the column. Mixtures were prepared a minimum of 30 minutes
before injection to ensure equilibration of the mixture.
2.7.2 Experimental Protocol
The SEC-MALS system was equilibrated in sizing buffer + 0.5 mM DTT (matching
the buffer used to prepare samples). Once the sizing column was fully equilibrated, the
flow into the MALS reference cell was stopped. 125 µL of sample was loaded into the 100
µL loop to ensure that it was fully loaded. Injection was programmed to occur after 10 mL
of buffer had flowed through the column since starting the program. MALS data were
collected and processed in ASTRA (Wyatt Technologies).

2.8 Analytical Ultracentrifugation
2.8.1 Sample Preparation for Analytical Ultracentrifugation
Frozen samples of proteins to be run PIP-UBM1(-UBM2) and Ub-PCNA were
thawed and individually injected into a GE S200 size exclusion column pre-equilibrated in
sizing buffer with 0.5 mM DTT. Peak fractions were collected and pooled in order to
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produce a sample of sufficient concentration directly from the sizing column. An additional
aliquot of the sizing buffer was kept on ice for use in the reference cell.
2.8.2 Analytical Ultracentrifugation Sedimentation Velocity Experiments
Sedimentation velocity experiments were performed to determine the stoichiometry
of the complex between polι and Ub-PCNA by measuring the molecular weight of species
in solution. UV absorbance optics were used to track sedimentation velocity.
Stored samples of Ub-PCNA and of PIP-UBM1 (or PIP-UBM1-UBM2) were
thawed and refreshed (as noted above) by size-exclusion chromatography using an GE
Superdex S200 column pre-equilibrated in Sizing Buffer with 0.5 mM DTT, which also
served to match the sample buffers. A 10 mL sample of the Sizing Buffer was kept separate
for sample dilutions and reference cells. 0.5 mL fractions were collected based on UV
absorbance. Peak fractions of each protein were pooled for a working concentration
(Roughly 5 mg/mL each for PIP-UBM1 experiments, and roughly 2.5 mg/mL each for PIPUBM1-UBM2 experiments).
Experiments using PIP-UBM1 were performed using a wavelength of 293 nm to
track Ub-PCNA only while leaving PIPUBM1 virtually invisible. Trimeric Ub-PCNA was
kept to a constant concentration 18 μM while PIP-UBM1 ratios were varied between cells.
Each individual experimental run included a Ub-PCNA standard cell to ensure reliability
since the expected mass change is so small.
The sedimentation velocity experiments were run at 20 ºC over a period of 7.5
hours, at a radially mean force of 89,180 g. Scans of absorbance vs radial length were
conducted at 10-minute intervals for a total of 45 scans. Cells depleted over the course of
the experiment.
Experiments using PIP-UBM1-UBM2 were performed using a wavelength of 280
nm to match the standard protein UV absorbance peak. The aromatic amino acid content,
and thus absorbance spectra, of Ub-PCNA and PIP-UBM1-UBM2 are similar, thus the
strategy employed in PIP-UBM1 experiments could not be applied here. Ub-PCNA trimer
concentration was kept constant in each cell, but at 4.5 μM to keep the absorbance low
enough to also track PIP-UBM1-UBM2. Ub-PCNA-only absorbance under these
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conditions was 0.5, which left room for higher ratios of PIP-UBM1-UBM2. The binding
partner ratio was varied to determine the possible complex stoichiometries.
Sedimentation velocity data were analyzed in the SEDFIT program (Schuck, 2000)
to produce a continuous c(s) distribution, with peaks corresponding to the observed
sedimentation coefficient (sw) of the species in solution. This sedimentation coefficient can
be used to estimate the molecular weight of the species in solution by the Svedberg
relationship:
𝑀
𝑠𝑓
=
𝑁𝐴 1 − 𝑣̅ 𝜌
Equation 1. The Svedberg relationship, where M is the molecular weight, NA is
Avogadro’s number, s is the sedimentation coefficient, f is the frictional coefficient, 𝑣̅ is
the partial specific volume, and ρ is the solvent density. The solvent density and partial
specific volume were calculated using SEDNTRP, a SEDFIT-suite program.
Analysis proceeded using a single frictional coefficient for all runs to try to avoid
biasing results. This coefficient was initially determined by fitting the Ub-PCNA standard
estimate to its known molecular weight and applying the same coefficient to each of the
remaining cells. The frictional coefficient is the relationship between the apparent size of
the molecule and its resistance to sedimentation, i.e. between two molecules of identical
molecular weight, the molecule with the smaller frictional ratio will sediment faster. This
value may be floated during analysis but changing its value will cause species with identical
sedimentation coefficient to have different apparent molecular weights. The frictional ratio
is determined by the shape and flexibility of the species. Since the Ub-PCNA trimer forms
the bulk of the PIPUMB1-Ub-PCNA complex, the frictional ratio of each complex should
differ little from that of Ub-PCNA on its own.
2.8.3 Analytical Ultracentrifugation Sedimentation Equilibrium Experiments
Sedimentation equilibrium experiments were performed to determine the
dissociation constants of the polι-Ub-PCNA complexes. Sample preparation was
performed in the same manner as the sedimentation velocity experiments. UV absorbance
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optics were again used to track sedimentation. Experiments were performed using 2-cell
centrepieces.
Experiments using PIP-UBM1 complexes were again performed using a
wavelength of 293 nm to simplify the system and track Ub-PCNA alone. Ub-PCNA trimer
concentration was held constant at 8.9 μM across all cells and three complexes were run:
Ub-PCNA alone, 1:2 trimer:PIP and 1:4 trimer:PIP. Samples were mixed in a 175 µL
volume, from which 150 µL were loaded into the sample cell. 175 µL buffer was loaded
into the reference cell.
Equilibrium experiments with PIP-UBM1 and Ub-PCNA were performed at 20 ºC
for a total of 87 hours. The PIP-UBM1 experiment was performed with the following
speeds and timepoints. The remaining mixed sample was mixed with SDS sample and
frozen so that an SDS-PAGE gel could be run to determine whether any degradation
occurred.
Experiments using PIP-UBM1-UBM2 were performed using a wavelength of 280
nm to maximize sensitivity. The absorbance spectra of PIP-UBM1-UBM2 and Ub-PCNA
are similar and there is not a convenient wavelength to observe only Ub-PCNA. Ub-PCNA
trimer concentration was held constant at 2.7 μM and three complexes were run: 1:0.8, 1:1,
and 1:2 trimer:PIP.
Equilibrium experiments with PIP-UBM1-UBM2 and Ub-PCNA were performed
at 20 ºC for a total of 68 hours. The PIP-UBM1-UBM2 complex equilibrium experiment
was performed with the following speeds and timepoints.
Based on the results of the PIP-UBM1 complex experiments, the speeds and
number of scans were reduced to improve the quality of the data. The experimental setup
used does not accurately measure the concentration at A > 1.1, thus at higher speeds larger
segments of each scan would be excluded from analysis. Since the most important part of
a scan is the most concentrated section, excluding this end may lead to unreliable data.
Data analysis of all SE experiments were performed using SEDPHAT’s multispeed equilibrium processing (Vistica et al., 2004). The analysis used a 3-site symmetric
binding model and treated the entire Ub-PCNA trimer as the central binding partner with
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three binding sites. This model was chosen because the observed particle is the Ub-PCNA
trimer in addition to its bound partners. Unfortunately, this model is much more
complicated than a standard heteroassociation A+B-type model.
𝐾𝐷𝐼 =

(𝐴 + 𝐴𝐵𝐼𝐼 + 𝐴𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼𝐼 𝐵𝐼𝐼𝐼 ) ∙ 𝐵
(𝐴𝐵𝐼 + 𝐴𝐵𝐼 𝐵𝐼𝐼 + 𝐴𝐵𝐼 𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼 𝐵𝐼𝐼 𝐵𝐼𝐼𝐼 )

𝐾𝐷𝐼𝐼 =

(𝐴 + 𝐴𝐵𝐼 + 𝐴𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼 𝐵𝐼𝐼𝐼 ) ∙ 𝐵
(𝐴𝐵𝐼𝐼 + 𝐴𝐵𝐼 𝐵𝐼𝐼 + 𝐴𝐵𝐼𝐼 𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼 𝐵𝐼𝐼 𝐵𝐼𝐼𝐼 )

𝐾𝐷𝐼𝐼𝐼 =

(𝐴 + 𝐴𝐵𝐼 + 𝐴𝐵𝐼𝐼 + 𝐴𝐵𝐼 𝐵𝐼𝐼 ) ∙ 𝐵
(𝐴𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼 𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼𝐼 𝐵𝐼𝐼𝐼 + 𝐴𝐵𝐼 𝐵𝐼𝐼 𝐵𝐼𝐼𝐼 )

Equation 2. KD equations in a three-site binding model. Each binding site is considered
separately (ABI, ABII, and ABIII) and each individual KD accounts for all possible
populations in equilibrium (9 in total). This model keeps all binding sites in saturation with
one another, rather than saturating each binding site stepwise.

2.9 Small-Angle X-ray Scattering Experiments (SAXS)
2.9.1 Size-Exclusion Chromatography – Small Angle X-ray Scattering
SEC-SAXS experiments (Malaby et al., 2015) were performed at the Advanced
Photon Source (APS) beamline 18D. Samples of Ub-PCNA and PIP-UBM1 were purified
and concentrated in lab and shipped to APS. 250 µL samples of complex were prepared 30
minutes prior to injection to allow for equilibration and then injected into a fast-flow S200
gel filtration column pre-equilibrated in SAXS buffer at room temperature inside the
beamline hutch. The beam wavelength was 1.54 Å. X-ray scattering images were collected
before, across, and after the peak through an inline capillary. This experimental setup uses
size exclusion chromatography to ensure that the sample is monodisperse (assuming good
separation on the column) and the inline capillary combined with low exposure per frame
reduces the effect of radiation damage on the sample collected. The capillary system is
thoroughly cleaned using hydrophobic liquid to prevent buildup of damaged proteins and
thus improve the quality of the data collected.
Basic SAXS processing was performed at the beamline using the RAW software
suite. Molecular weight (MW) and radius of gyration (Rg) measurements are easily
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processed and were used to assess the data quality. SAXS envelope modelling was
performed using DAMMIN (Svergun, 1999), DAMMIF (Franke and Svergun, 2009), and
GASBOR (Svergun et al., 2001). Visualization of the envelope was performed in PyMOL.
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3 Results
3.1 Purification of polι and (Ub)-PCNA proteins
3.1.1 PIP-UBM1-PCNA fusion proteins can be separated from contaminants.
Fusion proteins were developed for crystallization experiments. Protein complexes
crystallize best when one partner is saturated, but the excess of the other partner required
may inhibit crystallization. Fusion proteins create a saturated “complex” without any
excess binding partner.
Purifications proceeded according to the procedure outlined in Methods. A gel
would be run following the Ni column on the first day to assess quality. Fractions
containing few contaminating proteins and reasonable concentration would then be pooled.
The concentration of protein was then measured (typical total protein between 30-60 mg
per litre of culture used) and TEV protease was added.
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The next and final check occurs after the final ion exchange column.
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Figure 3.1 Fusion Protein Production a) Expression and solubility test for StrpII-PIPUBM1-PCNA protein, expressed with TEV-cleavable His-Mocr solubility and affinity tag.
1) uninduced cell lysate. 2) induced cell lysate after 4h growth at 37 °C. 3) soluble fraction
of 37 °C expression. 4) induced cell lysate after overnight growth at 16 °C. 5) soluble
fraction of 16 °C expression. The expression and solubility are typical of the fusion
proteins, save the little finger fusion proteins, which tend to be less soluble even after
overnight low-temperature growth. b) TEV digestion and final ion exchange fractions for
StrpII-PIP-36del-UBM1-PCNA fusion protein, an example of its type chosen because the
contaminant band is easily seen. A low molecular weight (Mw) array is used as a reference
standard with bands at 97.4, 66.2, 45, 31, 21.5, and 14.4 kDa. After successful TEV
protease (31 kDa) digestion of the tagged protein at 66 kDa (lanes 1-2), the digestion
product at 45 kDa was loaded on an anion exchange column (flowthrough in lane 3) and
eluted (lanes 4-14). Early peak fractions (5-10) can be pooled to exclude the major
contaminant at 40kDa.
PCNA alone tends to run higher than expected from its molecular weight (see
PCNA purification below), so it is not surprising that the fusion proteins do too. In this
case, the 40 kDa StrpII-PIP-36del-UBM1-PCNA fusion appears to run the same as the 45
kDa marker. The contaminant just below the main protein band is present in all fusion
proteins and can be removed by only pooling early peak fractions with minimal
contamination. It is not a degradation product; the pooled early fractions can be kept at
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room temperature for two weeks without any sign of degradation. PIP-UBM1-PCNA
proteins can be concentrated to approximately 15mg/mL safely.
The fusion proteins were not able to be ubiquitinated at K164 alone. Since sitespecific ubiquitination could not be achieved, the UBM had no binding partner and could
not be anchored to a specific region. This may have been a factor in the failure of the
crystallization trials.
3.1.2 Short polι C-terminal proteins are stable, longer forms are more delicate
Polι C-terminal proteins were the model proteins of choice for studying all aspects
of the interaction between polι and Ub-PCNA. PIP-UBM1 (aa415-530) is the workhorse
protein; it is stable, easy to purify, contains both major interacting motifs, and has no
internal deletions. It has been used for every experiment during this project. PIP-UBM1UBM2 (aa415-715) contains the entire C-terminal domain. It has been used for analytical
ultracentrifugation experiments to determine whether the full-length protein behaves in the
same manner as the truncated protein. PIP-UBM1-UBM2 more prone to aggregation than
the PIP-UBM1 protein and cannot be concentrated to the same concentration (m/v). Its
thermal stability is also poorer, but it does not have any significant effect at either 4 ºC or
20 ºC.
Purification of polι C-terminal proteins is straightforward and requires only two
columns. For the first day, the Ni column only requires a spot test check to pool fractions
and a Bradford assay to measure protein for TEV digestion (typical values are roughly 50100 mg per litre of cell culture).
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Figure 3.2 C-terminal protein production a) Expression and solubility test for PIP-UBM1
protein, expressed with TEV-cleavable His-Mocr solubility and affinity tag. 1) uninduced
cell lysate. 2) induced cell lysate after 4h growth at 37 °C. 3) soluble fraction of 37 °C
expression. b) Example SDS-PAGE gel outlining purification of PIP-UBM1 C-terminal
fragment as an example of this class of protein. After enrichment and purification of the
target protein by Ni-affinity chromatography (lane 5), the final anion exchange step
eliminates the bulk of the contaminants. The remaining weak contaminants are eliminated
by size-exclusion chromatography.
PIP-UBM1 proteins may be safely concentrated to 20 mg/mL but this is typically
unnecessary; 10-15 mg/mL is a typical target concentration. The low molecular weight of
the protein means that even this lower concentration has a high molarity. PIP-UBM1UBM2 proteins may be safely concentrated to 10 mg/mL.
3.1.3 PCNA purification is highly effective
PCNA is the basis for the other major component of the complex being studied. It
or Ub-PCNA has been used in all experiments in this investigation. Purification followed
the procedure outlined in Methods. Each PCNA monomer is tagged with a TEV-cleavable
8xHis tag. The protein forms a strong trimer, so the protein being purified may be treated
as a single unit with 3 such tags. The protein strongly binds the first Ni column and may
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be washed with high imidazole before elution and is pure after this first stage. Subsequent
purification steps are largely to separate the cleaved tag and the TEV protease.
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Figure

3.3

PCNA Production

a)

SDS-PAGE

gel

demonstrating

Ni-affinity

chromatography of His-PCNA. The 8xHis tag confers powerful Ni affinity to PCNA,
which permits stringent washing (lane 1) and elution (lane 2) of pure protein at the first
step of the purification. After tag removal, the 2nd Ni column traps nearly all the
contaminants, leaving pure PCNA in the second flowthrough fraction (lane 5). b) SDSPAGE gel of the final anion exchange step. Purity has not been improved between the load
and elution fractions, but the protein is now in a more appropriate buffer without leached
Ni and is contained in a smaller volume. The anion exchange chromatogram may also be
used as a quality check.
The final ion exchange column removes any nickel or imidazole that may still be
in the protein buffer and concentrates the protein before the final centrifugal concentration.
PCNA may be concentrated to 20 mg/mL, but typically 12-15mg/mL was used
since it must be diluted anyway during its ubiquitination reaction. Typical yield is 10-15
mg per litre of culture used. The protein was dispensed into 5 mg aliquots for ease of use.
Protein not immediately ubiquitinated was flash frozen and stored at -80 ºC. Frozen PCNA
may be ubiquitinated immediately after thawing; refreshing is achieved during the
ubiquitination protocol and the customary size-exclusion before the final use.
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3.1.4 Ubiquitin purification is high yield
Ubiquitin has been purified for the purpose of ubiquitinating PCNA. The ubiquitin
purification follows an atypical protocol, and at no point does the target protein bind to a
chromatography column. Anion exchange columns are used twice, but these only remove
contaminants and the ubiquitin remains in the flowthrough fraction. This causes the volume
of the buffer containing the protein to increase with each step. To accommodate the large
final volume, a pressure-fed concentrator with a 40 mL capacity and a 5000 Da MWCO
was used to concentrate the sample. The concentrator also had an internal magnetic stir bar
to prevent overconcentration near the membrane. Even with this concentrator the flow rate
was roughly 20 mL per hour. Once the total volume reached 10mL, the sample was
transferred to a 15mL centrifugal concentrator to finish concentrating. hUb was
concentrated to its working concentration of 18.6 mg/mL and had a final yield of 74.3 mg
from 4 L of cell culture. 150 µL aliquots were made and flash frozen for later use.
3.1.5 Ubiquitination reaction is high yield, scalable
PCNA is ubiquitinated in 50 mL conical tubes, in the reaction buffer outlined
above. The reaction buffer is then loaded on a Q column as outlined in Methods to isolate
the Ub-PCNA. The excess ubiquitin and enzymes do not bind the column at the loading
buffer’s ionic strength, and the Ub-PCNA that elutes from the column is pure.
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Figure 3.4 Ubiquitination Products SDS-PAGE gel demonstrating the final state of UbPCNA after anion exchange chromatography to remove the enzymes involved in the
reaction. Each numbered lane represents the sequential 1.4 mL peak fraction collected from
the Q column. The faint band below the strong Ub-PCNA band is the remaining PCNA.
Ub-PCNA is effectively pure at this stage.
Ub-PCNA can be concentrated to 20 mg/mL but is usually only concentrated to
15mg/mL. The same mass of Ub-PCNA can be recovered as the mass of PCNA used in the
reaction (~90% yield).

3.2 Difficulties in crystallizing PIP-UBM1/Ub-PCNA complex
PIP-UBM1-PCNA fusion proteins were screened for crystals using the screens and
experimental setups outlined in Materials and Methods. No protein crystals were observed
nor any promising phase separations. Fusion proteins appeared to be more susceptible to
aggregation compared to PIP-UBM1 + Ub-PCNA complexes of similar concentration,
which suggested that the fusion proteins were less stable than the natural complex. Certain
conditions (namely divalent cations, acidic pH, PEG range 4000-6000) tended to cause
immediate heavy aggregations; screens which were biased toward these conditions were
screened at lower concentrations initially then generally excluded from second-round
screenings.
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Natural complex (PIP-UBM1 and Ub-PCNA) screening had been attempted by the
laboratory before the beginning of this investigation, without success. After the completion
of fusion protein trials, the focus returned to the natural complex. Before returning to
crystallization trials, the natural complex was studied to challenge the assumptions that had
been made about it, particularly the specificity of the ubiquitination reaction and the excess
of PIP-UBM1 required to saturate the complex.

3.3 The ubiquitination reaction is site-specific and monoubiquitination-specific
A possible reason for the failure of a crystallization trial would be a heterogeneity
in the sample. In the case of the PIP-UBM1/Ub-PCNA complex, the most probable
heterogeneity would be the presence of multiple ubiquitination sites. The SDS-PAGE gel
of the ubiquitination product showed a single, strong band. Time-course experiments had
never shown an intermediate product that would suggest that the product was
polyubiquitinated, and a ubiquitination reaction that was oversupplied with ubiquitin and
reacted for twice the normal time did not produce any bands higher than the normal
product. These results demonstrated that the product of the ubiquitination reaction is
exclusively mono-ubiquitinated PCNA. The literature on the reaction used (Hibbert and
Sixma, 2012) had demonstrated that K164 was necessary for the reaction, but it did not
conclusively prove that there were not multiple mutually-exclusive possible monoubiquitination sites.
3.3.1 K164R mutant PCNA abolishes ubiquitination
The specificity test using K/R point mutations that was performed by Hibbert and
Sixma was extended to also investigate K168, which is the most likely off-target
ubiquitination site (Hibbert and Sixma, 2012). PCNA of wild-type, K164R, K168R, and
the K164/168R double mutant were purified for the experiment and then ubiquitination
reactions for each were run simultaneously. The SDS-PAGE gel of the ubiquitination
reactions is displayed below.
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Figure 3.5 Ubiquitination Assay by Point Mutation SDS-PAGE gel of ubiquitination
reaction for wild-type (WT) PCNA and three K/R PCNA mutants. Wild type PCNA is
ubiquitinated as a control and the reaction ends in a single band. The K164R mutation
abolishes the ubiquitination, leaving the PCNA band unchanged and no ubiquitinated
products. K168R has little effect, with the majority of the PCNA being ubiquitinated in the
same manner as wild type, suggesting that K168 is not a target of this reaction. The
K164/168R mutation also abolishes ubiquitination, as expected after the results of the
K164R mutation. These results strongly suggest that the reaction used is site-specific to
K164.
The results of these ubiquitination reactions show that K168R can be ubiquitinated
like wild-type PCNA, while K164R and K164/168R are unable to be ubiquitinated under
the reaction conditions used. This suggests that K164 is the sole lysine ubiquitinated by the
reaction. K168 may have a role in the reaction, since the K168R reaction did not go to
completion, but it does not appear to be a ubiquitination target. These results suggest that
the ubiquitination reaction is site-specific and that the products are homogenous. However,
it was prudent to continue to confirm the homogeneity of the reaction products.
3.3.2 Mass spectrometry experiments detect ubiquitination at K164 only
Identification of other possible ubiquitination sites was performed using in-gel
digestion of Ub-PCNA followed by mass spectrometry (Parker et al., 2009). After
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digestion, peptide fragments of Ub-PCNA were identified by MALDI-TOF mass
spectrometry.
The following peptide fragments of PCNA were detected by mass spectrometry. The
underlined peptide is the sole fragment found with the GG scar from ubiquitination.
Table 3.1 Tryptic digest products of Ub-PCNA identified by MALDI-TOF.
Mass (Da)

Peptide from Sequence

653.3

MFEAR

754.4

YYLAPK

778.3

IEDEEGS

857.5

LVQGSILK

871.4

VSDYEMK

884.5

IADMGHLK

894.4

MPSGEFAR

932.5

YLNFFTK

974.4

SEGFDTYR

1261.6

CAGNEDIITLR (with carbamidomethyl adduct)

1293.6

FSASGELGNGNIK

1381.7

NLAMGVNLTSMSK (with oxidation)

1615.9

ILKCAGNEDIITLR (with carbamidomethyl adduct)

1984.0

DLSHIGDAVVISCAKDGVK (with GG scar)

2075.0

AEDNADTLALVFEAPNQEK (with carbamidomethyl adduct)

2424.3

ATPLSSTVTLSMSADVPLVVEYK (with oxidation)

2665.3

DGVKFSASGELGNGNIKLSQTSNVDK

3307.6

LSQTSNVDKEEEAVTIEMNEPVQLTFALR (with oxidation)
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MFEARLVQGS ILKKVLEALK DLINEACWDI SSSGVNLQSM DSSHVSLVQL
TLRSEGFDTY RCDRNLAMGV NLTSMSKILK CAGNEDIITL RAEDNADTLA
LVFEAPNQEK VSDYEMKLMD LDVEQLGIPE QEYSCVVKMP SGEFARICRD
LSHIGDAVVI SCAKDGVKFS ASGELGNGNI KLSQTSNVDK EEEAVTIEMN
EPVQLTFALR YLNFFTKATP LSSTVTLSMS ADVPLVVEYK IADMGHLKYY
LAPKIEDEEG S
Figure 3.6 Coverage map of PCNA by MALDI-TOF fragments. Highlighted regions are
those covered by the fragments detected by mass spectrometry. The red highlighted K
residues are the three lysine residues not covered by the peptides.
These data show a single peptide containing a GG shift. This peptide contains two
lysine residues: K164 and K168. It is unlikely that the K168 residue is the site of
modification; the GG scar is expected to cause a missed cleavage at scarred residue and the
cut site of the scarred fragment is at K168. It is also unlikely that there are ubiquitinations
at the sites not detected. The sample was taken from a gel band containing solely
monoubiquitinated PCNA, and there is no evidence of any unmodified K164. Furthermore,
two of the unmapped lysines are on the internal pore of the PCNA trimer and are difficult
to access for ubiquitination.
The results of this experiment confirm that the ubiquitination reaction created
mono-Ub-PCNA site-specific to K164 within the detection range of the mass spectrometry
experiment. Heterogeneity of the Ub-PCNA sample is not a probable cause of the failure
of the crystallization trials.

3.4 SEC-MALS experiments demonstrate stability of 1:1 complex
Once crystallization trials were abandoned, other avenues of studying the structure
of the complex were considered. SEC-MALS was considered as a starting point to
characterize the complex ratio and the stability of the complex over time. A Ub-PCNA
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trimer has binding sites to completely accommodate three PIP-UBM1 binding sites. Prior
ITC studies have demonstrated that Ub-PCNA has good affinity for PIP-UBM1, with
micromolar Kd. Size-exclusion chromatography experiments were able to separate the
complex from unbound Ub-PCNA and PIP-UBM1. However, it has not been possible to
distinguish between different ratios using the sizing column based on elution position, and
the PIP-UBM1 protein has poor UV absorption which make it difficult to estimate the
excess separated by the column. The combination of these factors may have contributed to
an erroneous assumption that the PIP-UBM1/Ub-PCNA complex was reasonably saturated
with a small excess of PIP-UBM1.
Table 3.2 Table of theoretical molecular weights of PIP-UBM1 and Ub-PCNA complexes.
Species
Theoretical
MW (kDa)

PIP-

Ub-PCNA

UBM1

(trimer)

13.3

111.9

1:1 Complex

1:2 Complex

1:3 Complex

125.2

138.5

151.8

SEC-MALS experiments were performed to determine whether a complete PIPUBM1 complex could be formed and determine whether the complex is stable enough to
survive size-exclusion chromatography.
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Elution Time (minutes)
Ub-PCNA Alone

Sample Run

30

1:4.5 Ub-PCNA:PIP

1:9 Ub-PCNA:PIP

Ub-PCNA

1:4.5 Ub-PCNA:PIP

1:9 Ub-PCNA:PIP

108.86 ±0.81

118.14 ±0.8

118.31 ±0.97

Figure 3.7 Multi-angle light scattering refractive index vs elution volume and chart
showing measured molecular weight. The red peak has Ub-PCNA Alone, the yellow peak
has 9:2 PIPUBM1:Ub-PCNA (trimer), and blue has: 9:1 PIPUBM1:Ub-PCNA (trimer).
The 9:2 and 9:1 peaks have identical elution volumes and estimated molecular weight.
Good single peaks were observed for all complexes, well separated from the excess
PIP-UBM1 peak further down. Complexes elute earlier than the Ub-PCNA alone; the shift
is small but definite. The two complex ratios do not have a notable difference in the elution
volume.
The mass estimation and complex ratio results were unexpected. Even at a UbPCNA concentration of 7.7 µM and a 2:9 ratio of Ub-PCNA:PIP-UBM1, the largest stable
complex that can be measured from the column is only a 1:1 Ub-PCNA(trimer):PIP. There
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is no change in the observed weight even after doubling the ratio of ligand to trimer. Given
that ITC experiments had determined the Kd of the interaction to be on the order of 5 µM,
this was a great surprise and suggested that the assumed complex ratio may have been
incorrect.

3.5 Complex investigation using analytical ultracentrifugation
The complex ratio observed in the SEC-MALS experiments did not match the prior
expectations, so the next step was to characterize the complex in solution by a different
method. Sedimentation velocity experiments were performed as outlined in Materials and
Methods to estimate the molecular weight of the complexes present at varying ratios of
PIP-UBM1 and Ub-PCNA. Once the range of possible complexes was determined,
sedimentation equilibrium (AUC-SE) experiments were performed to determine the
binding constants of the complex.
3.5.1 Sedimentation velocity experiments observe a maximum complex ratio of 1:2
The first set of AUC-SV experiments were performed using PIP-UBM1 and UbPCNA. PIP-UBM1 was the protein used to compare the results to those of the initial SECMALS experiments that showed unexpected complex behaviour.
Each experimental cell contained 2 mg/mL Ub-PCNA (18 µM trimer). Cells were
set up with the following ratios of Ub-PCNA:PIP-UBM1: 1:0, 1:1, 1:3, 1:6, and 1:9. This
concentration produced an absorbance value of 1 in the setup used, which gave a reliable
signal with a small noise component. At the wavelength chosen (293 nm) PIP-UBM1 is
nearly invisible (see Figure 3.8) but Ub-PCNA absorbance is still reasonably strong.
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PIP-UBM1 UV Absorbance Spectrum
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Figure 3.8 Absorbance spectrum of PIP-UBM1. 280nm is a standard UV wavelength for
measuring the concentration of protein. This absorbance is primarily from aromatic
residues (Phe, Tyr, Trp). Tryptophan has a larger aromatic system and permits the
absorbance of longer wavelengths. PIP-UBM1 lacks tryptophan residues, and the
absorbance spectrum above shows weak absorbance in the 290-300 nm region.
The samples were mixed to 400 µL. The experiments were performed using 2sector cells. 380 µL of sample were loaded into the sample cell and 400 µL of Sizing Buffer
was loaded into the corresponding reference cell.
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Figure 3.9 AUC-SV of PIP-UBM1/UbPCNA complex a) full range of sedimentation
coefficients observed in solution during Ub-PCNA-PIPUBM1 AUC-SV experiments. c(s)
curves are normalized to the peak value. No significant impurities or additional species are
observed. PIP-UBM1 is virtually invisible at the chosen wavelength by design, save the
small peak at 1.5 s during the maximum concentration run (9:1 ratio, red curve). b) section
of the data focusing on Ub-PCNA and complexes to better illustrate the shift of
sedimentation coefficient as the ratio of Ub-PCNA:PIP-UBM1 increases. The single peak
in each run suggests that multiple states are in equilibrium in each case and the interchange
is much faster than the timecourse of the experiment.
Table 3.3 Sedimentation coefficients and estimated molecular weights for PIP-UBM1/UbPCNA complexes, with inferred complex ratio.
Solution Ratio
1:0
1:1
1:3
1:6
1:9

Sw
5.0
5.4
5.5
5.6
5.7

MW (kDa)
115
125
130
136
137

Complex Ratio
1:0
1:1
1:1.5
1:2
1:2

Theoretical Mw
111.9
125.2
138.5
138.5

Sedimentation coefficients are listed as Sw after conversion to the theoretical
sedimentation coefficient in water. The probable complex ratio of each sample was
determined based on theoretical molecular weights for PIP-UBM1, Ub-PCNA, and their
possible complexes. Refer to Table 3.2 for theoretical molecular weights of the component
proteins and possible complexes.
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These molecular weight estimates suggested that each Ub-PCNA trimer can bind
two PIP-UBM1 partners, not the three that had been originally assumed. There was
virtually zero shift between the mass estimation of the 1:6 and the 1:9 runs, which suggests
that the complex is the upper limit on the complex ratio. The 1:1 peak is broad, which
suggests that it is not a homogenous complex but rather a mixture of 1:0, 1:1, and 1:2
complexes, with an average molecular weight corresponding to 1:1. This heterogeneity
suggests that the two Kd values are close enough to be in equilibrium with one another.
One incidental finding is the excess of PIP-UBM1 required to saturate the UbPCNA ring may have had an impact on crystallization experiments. Most crystallization
trials had been performed with a ratio between 1:3 and 1:4.5 (trimer:PIP), but the results
of this experiment suggest that the complex is not saturated in this condition.
Crystallization experiments are most likely to succeed when performed using a
homogeneous protein sample, and these AUC-SV experiments may have provided insight
into the failure to crystallize the complex.
The main possible source of error in this experiment is the estimation of the
molecular weight. The sedimentation values (s) are the direct product of the experiment.
The molecular weight is estimated from this based on factors like partial specific density
and the estimated shape of the particle. The molecular weight of Ub-PCNA was known
and used to estimate the mass of the complexes. However, the shift in s is so small between
complexes that the estimated molecular weights may have been incorrect and so the
estimated complex ratio would be incorrect as well.
3.5.2 AUC-SE experiments suggest that the first and second additions are of similar affinity
and in equilibrium
Having determined the range of possible complexes by AUC-SV, further
experiments were needed to measure the dissociation constant. Sedimentation equilibrium
experiments were performed to determine the dissociation constants of the PIPUBM1/UbPCNA complex. Complex stoichiometry and sedimentation coefficients were determined
by sedimentation velocity experiments and used to inform the experimental design of the
SE experiments. Once again, a wavelength of 293 nm was used to keep the PIP-UBM1
nearly invisible and only track the position of Ub-PCNA and its complexes. A Ub-PCNA
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concentration of 8.9 µM was chosen to achieve an absorbance of 0.4 AU when the cell is
at rest. This is to balance the need for a high enough concentration for a reliable signal with
the tendency for the absorbance at the bottom of the cell exceed the detector range. Prior
ITC experiments had determined a Kd value near 5 µM, so the final concentration of 8.9
µM is appropriate. Cells were run with ratios of 1:2 and 1:4 Ub-PCNA:PIP-UBM1, which
were chosen based on the qualitative assessment of the AUC-SV c(s) distribution. The
multi-speed equilibrium experiment was conducted using the following cell conditions and
speed settings.
Table 3.4 Speed/time settings for PIP-UBM1/Ub-PCNA AUC-SE experiment.
Scan #

Mean RCF (g) Hours between Scans

Total Hours

1

4,660

26

26

2

4,660

4

30

3

7,280

15

45

4

7,280

4

49

5

14,270

15

64

6

14,270

4

68

7

23,580

15

83

8

23,580

4

87

When setting a speed, a long period of time was left to allow for equilibration in the cell.
A second scan was performed 4 hours later at each speed to confirm that equilibration had
completed by overlaying scans. Each cell came to equilibrium successfully, but it was
found that at the two highest speeds the proteins had sedimented too much and were not
able to provide any useful data. Similar issues were found with the 4:1 cell. For that reason,
they were excluded from analysis and the speeds chosen were adjusted for the PIP-UBM1UBM2 experiments.
Data analysis was performed in SEDPHAT using the 3-site symmetric model, using
the Ub-PCNA trimer as component A and PIP-UBM1 as component B. The sedimentation
values of Ub-PCNA and the two observed complexes were given to the program, as was
an extrapolated value for the hypothetical “saturated” complex.
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Figure 3.10 Sedimentation equilibrium fit for PIP-UBM1/UbPCNA. Upper graph:
absorbance vs radial length for 4,660 g (green) and 7,280 g (red). Lower graph: residuals
of the fit. Data is cut off before the end of the cell as absorbance exceeds A=1. Overall fit
is good, the residuals are not perfectly randomly distributed as might be hoped.
Table 3.5 Dissociation constants for PIPUBM1/Ub-PCNA complex determined by
sedimentation equilibrium.
Kd1

Kd 2

Kd 3

χ2

1.01 ± 0.36 µM

2.85 ± 1.22 µM

>>Kd1

0.312

Dissociation constants were determined with a 95% confidence interval. These
values agree with the qualitative observations of the sedimentation velocity experiment.
Both experiments suggest that Ub-PCNA can host only two PIP-UBM1 binding partners
despite containing 3 sets of binding sites. In this case, the Kd3 is so large that the program
has effectively not observed any contribution and offered an absurdly large value as a
placeholder. The two real Kd estimates are close enough that they are in equilibrium with
one another, rather than sequential addition. This agrees with the peak broadening seen in
the SV experiments. Finally, the real Kd estimates are both in the magnitude of the prior
ITC experiments.
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Despite best efforts, it is possible that the shift in the s value is so small and the 3site binding model is so complex that these values represent an overfitting of the data.
Sedimentation values from the AUC-SV experiment were used as a guide for the fit,
possibly introducing an improper bias into the analysis.
3.5.3 Sedimentation velocity experiments with PIP-UBM1-UBM2 show similar 1:2
binding limit.
Sedimentation velocity experiments were then run using the larger PIP-UBM1UBM2 protein. PIP-UBM1 is a convenient protein of the polι C-terminal domain, but it is
a small representative part of that larger domain. Since the ratio of complex using the small
PIP-UBM1 fragment had been determined, the next step was to determine the complex size
limit using the larger PIP-UBM1-UBM2 protein and whether the larger domain would face
similar constraints. PIP-UBM1-UBM2 contains the entire suite of interacting motifs in the
C-terminal domain; it would be more representative of the biologically relevant complex
than the small fragment used in most experiments. Ub-PCNA was run alone as a reference
standard at a concentration of 4.5 µM, and mixtures of Ub-PCNA:PIP-UBM1-UBM2 were
run at ratios of 1:1 and 1:4.
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c(s) Distribution of UbPCNA + PIP-UBM2
Complexes
1

c(s)

0.8
0.6
0.4
0.2
0
0

2

4

6

8

10

s
1:1

UbPCNA Alone

4:1

Sample Ratio

Sw

MW (kDa)

Complex Ratio

Theoretical Mw

1:0

5.0

115

1:0

111.9

1:1

5.7

137

1:1

146

1:4

6.5

158

1:2

180.1

Figure 3.11 AUC-SV of PIP-UBM1-UBM2/Ub-PCNA complex Observed c(s)
distribution of PIP-UBM1-UBM2 and Ub-PCNA mixtures, estimated molecular weights,
and estimated stoichiometry of the observed complexes. As with the PIP-UBM1 AUC-SV
experiment in figure 3.8, single intermediate peaks are observed as a result of rapid
interchange at equilibrium.
The molecular weight estimates were not as accurate as the PIP-UBM1 results, but
they were enough to interpret the data. The higher molecular weight estimate suggested
that the complex was sedimenting faster than its actual molecular weight would suggest.
This was unexpected since unstructured proteins are generally assumed to sediment more
slowly than a structured globular protein. PIP-UBM1-UBM2 appeared to adopt a
maximum 1:2 complex with Ub-PCNA. If the first addition binds ubiquitin moieties with
both UBMs, the second addition can only bind with one of its two UBMs, which would
make the second addition less stable. The 1:2 peak has not sharpened to match the UbPCNA, suggesting that the complex has not fully saturated and may explain why the
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molecular weight estimate is below the theoretical 1:2 weight. This also suggests that the
second addition may be weaker than the second addition in PIP-UBM1.
3.5.4 AUC-SE experiments with PIP-UBM1-UBM2 show similar binding pattern to PIPUBM1
Sedimentation equilibrium experiments were performed to determine the
dissociation constants of the PIPUBM2-Ub-PCNA complex, again using the multi-speed
equilibrium setup. The wavelength chosen for absorbance measurements was 280 nm,
which was chosen to maximize sensitivity given there is not an available wavelength to
observe Ub-PCNA but not PIP-UBM1-UBM2. The concentration of Ub-PCNA (2.7 µM)
was again chosen to balance minimum and maximum absorbance. Ratios of 1:1 and 1:2
Ub-PCNA:PIP-UBM1-UBM2 were run in two cells.
Table 3.6 Speed/time settings for Ub-PCNA/PIP-UBM1-UBM2 AUC-SE experiment.
Scan #

Mean RCF (g)

Hours Before Scan

Total Hours

1

4,660

26

26

2

4,660

4

30

3

7,280

15

45

4

7,280

4

49

5

10,480

15

64

6

10,480

4

68

The scanning method was adjusted based on experience with the PIP-UBM1
complex. The speed of the third scan was reduced to improve the data range and the fourth
scan was omitted. Data processing was performed in the same manner as the PIP-UBM1
complexes above.
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Figure 3.12 Sedimentation equilibrium fit for PIP-UBM1-UBM2/UbPCNA. Upper graph:
absorbance vs radial length for 4,660 g (blue), 7,280 g (yellow) and 10,480 g (red). Lower
graph: residuals of the fit. Data is cut off before the end of the cell as absorbance exceeds
A=1. Overall fit is good, the residuals are not perfectly randomly distributed as might be
hoped, and the goodness of fit breaks down toward the bottom of the cell.
Table 3.7 Dissociation constants for PIP-UBM1-UBM2/Ub-PCNA complex determined
by sedimentation equilibrium.
Kd1

Kd 2

Kd 3

χ2

0.38± 0.04 µM

23.0± 1.32 µM

>>Kd1

0.671

Dissociation constants were again determined with a 95% confidence interval.
These Kd values for the PIP-UBM1-UBM2/Ub-PCNA are consistent with those found for
PIP-UBM1. The overall pattern is similar, but they show higher affinity for Kd1, lower
affinity for Kd2, and Kd3 is so large that the addition has not been observed. The decrease
in Kd2 may be caused by increased crowding effects, but the difference between the Kd2
values is so small that it may not reflect any actual difference.
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3.6 Reprocessing of ITC data
Isothermal titration calorimetry experiments had been performed by the lab prior to
this study. The experiment had assumed that each Ub-PCNA subunit would be able to host
a PIP-UBM1 partner simultaneously, so the analysis considered the protomer Ub-PCNA
as the binding partner of interest.

Figure 3.13 Original ITC data analysis, against Ub-PCNA protomer. The n value is very
nearly 1, and there is no reason to suspect that the maximum stoichiometry is anything but
1:1 (equivalent to 1:3 Ub-PCNA (trimer):PIP-UBM1).
This result appears to rest on incorrect assumptions, based on the AUC experiments,
therefore it was prudent to reinterpret the data considering the new observation. Ub-PCNA
concentration was reset to consider the trimer as the particle of interest, and the n value
was set to float between 2.5 and 3.5 to represent the total number of available binding sites.
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Figure 3.14 ITC isotherm for trimeric Ub-PCNA vs PIP-UBM1. The n value is nearly 3
and does not show any indications that the Ub-PCNA is not being fully saturated by PIPUBM1. The approach to complete binding occurs between the mole ratio of 5-6, which is
also the saturation point observed in the AUC-SV results.
ITC reprocessing does not show any signs that the Ub-PCNA trimer cannot be
saturated by PIP-UBM1. The n value of 3.021 is a perfect match for complete saturation
of the Ub-PCNA ring. It is possible that ITC cannot be used to determine the ratio of the
complex. The Kd value 10 µM is a fair match for the AUC values (Kd = 1.01 and 2.85 µM).
Considering that the ITC analysis is attempting to fit 3 identical binding sites, the
underestimation of the Kd is unsurprising. Overall this experiment indicates that the AUCSV experiment is likely measuring the strength of the binding well.
ITC has the fewest sources of error for investigating binding, so long as the protein
concentrations are accurately measured. Its main shortcoming is that the software used to
analyze it cannot separate sequential bindings. Rather than Kd1, Kd2, and Kd3, it returns a
single Kd value and an n value for the binding ratio.
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3.7 Solution structure study by small-Angle X-ray scattering
Small-angle X-ray scattering (SAXS) experiments were a good complement to the
MALS and AUC experiments, and an opportunity to get structural information about the
complex. A single set of experiments were able to provide both types of information.
3.7.1 SAXS measurements of Ub-PCNA are in line with literature values, the 1:1 complex
with PIP-UBM1 can be detected after SEC
Experimental runs were performed using Ub-PCNA alone, PIP-UBM1 alone, 3:1
PIP:Trimer, and 2:1 PIP:Trimer. In mixtures containing Ub-PCNA, its concentration was
5.3 mg/mL (47 µM) and PIPUBM1 was added to achieve the ratio required. PIP-UBM1
alone was run at a concentration of 11.6 mg/mL (872 µM) to maximize scattering of the
small protein.
Table 3.8 Sample injection conditions for SEC-SAXS experiments.
Injection Number

1

2

3

4

Ub-PCNA Trimer (µM)

47.4

47.4

0

47.4

PIP-UBM1 (µM)

0

142.8

872.2

97.7

Injection Size (µL)

250

250

250

250

Ratio Trimer:PIPUBM1

1:0

3:1

0:1

2:1

Data were collected as a series of images and initial data processing was performed
using the RAW analysis suite, followed by ab initio modelling using DAMMIN,
DAMMIF, and GASBOR.
Basic SAXS processing was performed at the beamline using the RAW suite.
Molecular weight (MW) and radius of gyration (Rg) measurements are easily processed
and were used to assess the data quality. Ub-PCNA and the complex were both of good
quality: each had higher molecular weights than theoretical but within the acceptable range
for the experiment, and each had consistent Rg across the peak. These suggest that the
sample quality was good and that the sample was monodisperse across the peak. PIPUBM1 alone did not scatter well enough to measure Rg but its molecular weight was
consistent with the theoretical.
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The following molecular weights and Rg values were measured during each run.
Also included is the Dmax estimate. Dmax is a user-generated parameter and represents the
longest linear dimension of the particle. Rg and Dmax values for Ub-PCNA are in line with
values previously reported (Hibbert and Sixma, 2012).
Table 3.9 Basic SAXS measurements for Ub-PCNA, PIP-UBM1, and complex.
Sample

Mw (kDa)

Theoretical Mw

Rg

Dmax (Å)

Ub-PCNA

118

111.9

39.9

127

PIP-UBM1

13.7

13.3

N/A

N/A

1:1 Complex

138

125.2

44.5

157
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a

b

Figure 3.15 Ub-PCNA and Complex SAXS comparison (a) Pair distance distribution
functions (PDDF) and (b) plotted I(q) vs q (intensity vs scattering angle) for Ub-PCNA
alone and PIP-UBM1/Ub-PCNA complexes. Ub-PCNA: red and blue curves. Complex:
purple and green. These demonstrate that there is a measurable difference between the UbPCNA and the complex. The PDDF graph shows that the complex is a physically larger
particle, with a larger Dmax and larger average dimensions. The PDDF is also of
approximately the correct shape. PCNA itself is ring shaped, while the ubiquitin moieties
are placed at the outer edge and all face towards one of the faces. The overall shape of each
plot is intermediate between the disc pattern and the sphere pattern, which is consistent
with the structure of the molecule. The I(q) plot shows that the proteins are in good shape,
and again has an observable difference between the complex and the Ub-PCNA alone.
3.7.2 SAXS envelope modelling can reconstruct Ub-PCNA, reconstruction of the complex
is ambiguous
Ab initio structure modelling of Ub-PCNA and the complex was performed to
create a model of the shape of the Ub-PCNA alone and the complex. DAMMIF/N and
GASBOR were both tested before GASBOR was chosen. DAMMIF/N’s dummy atom
modelling had difficulty generating a pore to locate the PCNA ring. Averaging and
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clustering also showed that the reconstruction was ambiguous and many possible models
could fit the data. GASBOR’s dummy residue model created more interpretable envelopes
and produced particularly good Ub-PCNA envelopes.

Ubiquitin

PCNA

Figure 3.16 Reconstructed model of Ub-PCNA using GASBOR dummy residue
modelling. This model is looking toward Ub-PCNA’s rear face, with the plane of the ring
parallel with the page, and the ubiquitin domains pointing toward the reader.
This is a good reconstruction of Ub-PCNA in solution from low-resolution data.
The PCNA pore is apparent, the pseudo-P6 symmetry of the PCNA ring looks to be in
place, and the ubiquitin domains are placed in a semi-extended position. This
reconstruction was achieved by enforcing P3 symmetry on the model. Unfortunately, this
strategy cannot be applied to the complex reconstruction.

58

a

b
PIP-UBM1

Ub-PCNA

PIP-UBM1

Figure 3.17 Reconstructed model of PIP-UBM1/Ub-PCNA 1:1 complex using GASBOR
dummy residue modelling. Left image shows the PCNA ring in plane of the page, right
image shows the PCNA ring perpendicular to the plane. PIP-UBM1 is believed to appear
as the bulge on the right in image A and above on image B.
The complex is only expected to have one PIP-UBM1 based on the observed
molecular weight, so the symmetry of the complex is P1. This leaves the modelling
program with fewer constraints. The reconstructions of the complex did not average or
cluster well, which suggests that the data may be ambiguous, and the complex
reconstruction is a best guess. Tentatively, the reconstruction appears to be in a transarrangement, with a wide, distributed mass of PIP-UBM1 along a side of Ub-PCNA. The
cis- arrangement would be expected to be a narrow, clustered mass. This transarrangement may be a reason for the limited complex ratio observed in sedimentation
velocity experiments.
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4 Discussion
4.1 The observed complex ratio between Ub-PCNA and polι is limited to two polι
for each Ub-PCNA ring
At the beginning of this research project, the operating assumption that the complex
between PIP-UBM1 and Ub-PCNA was straightforward: each Ub-PCNA protomer could
host a single PIP-UBM1. Each PIP-UBM1 had a pair of binding motifs which bound to the
complementary pair of binding sites on Ub-PCNA. We assumed that PIP-UBM1 was small
enough (117aa) to be accommodated in multiple bindings on Ub-PCNA.
The initial SEC-MALS findings, with its hard cap of a 1:1 complex, were not
expected but inconclusive. Even a large excess of PIP-UBM1 was not able to increase the
measured molecular weight of the complex. The similar SEC-SAXS experiment confirmed
the observation, but both shared the SEC component of the experimental setup. This system
had the advantage of separating the complex from the excess binding partner. It was
therefore possible that the 2nd and 3rd bindings were simply being shorn off as it flowed
through the column. The difference in the speeds of the columns and the temperature during
the columns may have contributed to the different MW estimates. To prove that the
observed complex ratio was not an experimental artifact, another type of experiment had
to be conducted.
Sedimentation velocity experiments were a perfect complement to the previous
experiments. Like SEC-MALS and SEC-SAXS it provided a good estimate of molecular
weight, but it did so with a completely different experimental method (sedimentation
velocity vs. light scattering). This method also keeps the complex in question surrounded
by the excess binding partner. Rather than stripping away excess protein, the complex
sediments through a sea of excess protein and should maintain its state through the entire
experiment. These experiments broadly agreed with the scattering experiments in that a 1:1
complex forms readily but differed in demonstrating that a 2:1 complex is achievable with
enough excess PIP-UBM1. The second addition is likely present in some proportion of the
population in the “1:1” experiment, along with an equal proportion of free Ub-PCNA. This
heterogeneity would be a hindrance to further crystallization experiments.
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Polι has moderately strong affinity for Ub-PCNA, as measured by ITC experiments.
In both ITC and AUC experiments using PIP-UBM1 and Ub-PCNA, the complex appears
to reach its final state at a ratio between 1:4 and 1:6. The apparent limit may be caused by
the weak, dynamic binding, but the ease with which the first two additions occur suggests
there may be a crowding factor that could be confirmed by structural studies.

4.2 Comparison of methods to investigate binding behaviour
Analytical ultracentrifugation and isothermal titration calorimetry were used to
investigate the binding of the complex. Sedimentation velocity experiments measured the
molecular weight of the complex to determine the complex ratio, followed by equilibrium
experiments to determine the dissociation constants. This method was chosen to observe
the complex in solution with a large excess of its binding partners, unlike experiments that
relied on a size exclusion column. Sedimentation equilibrium experiments were also able
to determine each Kd separately and use those to make inferences about cooperativity in
the binding.
Isothermal titration calorimetry experiments were used primarily for the
determination of a dissociation constant. The n value was also used as an indicator of the
complex ratio. ITC returns a single Kd, which represents an average of the three separate
bindings.
ITC is a much simpler method, with fewer sources of error than the AUC
experiments. Fitting a binding curve to the data has fewer degrees of freedom. Determining
the dissociation constants by AUC in a three-site system has more degrees of freedom and
therefore it can be difficult to conclude that the determined Kd values are accurate. Adding
to this complexity, the data analysis requires determination of sedimentation and
absorbance values for participating species, which introduces numerous possible sources
of error. The sedimentation coefficients themselves are a possible source of error. Even if
AUC-SV experiments determine accurate sedimentation coefficients, they must be
converted to a molecular weight to be intelligible. Since the shift in mass is so small (each
PIP-UBM1 added is only 11% of the mass of Ub-PCNA) it is possible that a small error in
the mass calculation may lead to a misidentification of the complex observed. These errors
combined make the AUC results less conclusive, so the disagreement of the n value from
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ITC and the complex ratio found in AUC is troubling. It may be wise to take the AUC
results as provisional at best, but it would be useful to consider their implications if they
are borne out by further experiments.

4.3 Complex structure predictions
Explicit structure determination by crystallographic and SAXS methods may have
failed, but some predictions of the structure may be made. Ub-PCNA appears to be able to
accommodate a maximum of two polι based on AUC experiments. Although both additions
are in equilibrium with one another, SEC-MALS data suggests that the single-binding
arrangement is the most stable over long time courses. Combined with the unobserved third
binding, this suggests that there is a crowding effect that affects each subsequent binding.
This crowding is suggestive of a trans-binding arrangement. A cis-binding arrangement is
not necessarily immune to crowding effects, but the trans arrangements is virtually certain
to cause this effect.
A definitive reconstruction of the SAXS envelope of the complex was not possible,
but the best reconstructions tended to have broad regions assigned to the PIP-UBM1
section. This may indicate that the complex is in dynamic equilibrium during the SECSAXS experiment. Based on AUC-SV experiments, the apparent 1:1 complex may be an
n equilibrium between the 1:0, 1:1, and 1:2 species. The SEC-SAXS method is normally
employed to isolate species and capture scattering from a homogenous sample. In this case,
a “1:1” sample may have quickly reached a new equilibrium state that could not be further
isolated by the size exclusion column.
The polι/Ub-PCNA complex studied here may not be entirely biologically relevant.
The TLS complex also includes Rev1 as a scaffold protein, and ubiquitinated polη is
necessary for polι recruitment (Vaisman and Woodgate, 2017). It is possible that one or
both UBMs may prefer to bind to other ubiquitinated proteins in the complex in vivo. Polι’s
direct interaction with Ub-PCNA is still a matter of interest, as no structure of any Y-family
C-terminal domain in complex has been solved. Models for TLS function rely on inferences
from function experiments and molecular simulations. Solving the polι/Ub-PCNA complex
would be an important part of modelling the overall TLS complex.
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4.4 Implications for TLS mechanism and polymerase selection
The observation that truncated polι proteins cannot form a 1:3 complex with
trimeric Ub-PCNA suggests that it is a poor candidate to participate in tool belts. The toolbelt model of lesion bypass requires Ub-PCNA to host several TLS polymerases, each of
which may probe the lesion. This increases the probability that the most efficient, and
therefore likely the most suitable, polymerase performs the bypass. Tool-belts have been
formed in vitro using PIP-containing proteins and a two-part tool belt of polη and Rev1 has
been observed in yeast in vivo (Boehm et al., 2016). Y-family polymerases, which are the
primary TLS polymerases, all have large, unstructured C-terminal domains that bind to UbPCNA.
There is variation in C-terminal organizations between the Y-family polymerases
(Figure 1.1). Polι cannot easily form tool belts even as the only available polymerase,
where all three hypothetical proteins would be able to adopt the same arrangement to
minimize crowding effects. It therefore seems unlikely that it would readily form tool belts
alongside differently organized proteins like other members of the Y-family.
While this finding does not exclude the possibility of tool belts within TLS, it
demonstrates that polι is not suited to participating in them. If the tool-belt model is
validated in humans and the other TLS polymerases form functional tool-belts in vivo, then
that suggests that polι acts as a last-resort option. Polymerase ubiquitination (as outlined in
the polymerase switch model) would also be at work in a tool-belt system. A lesion for
which none of the tool-belt polymerases are suited would continue to stall replication. The
first-response tool-belt polymerases would then continue to bind, probe, and be deactivated
by ubiquitination. Eventually the local pool of these polymerases would deplete until their
local concentrations dropped to the point that tool-belt formation could not continue, at
which point polι would be able to bind Ub-PCNA and engage the lesion. Polι’s role in this
model would be that of a last-line lesion specialist. Since it would only be activated rarely,
this model would account for polι’s apparent low importance to organism survival; polι
knockout mice being apparently healthy unlike XPV patients (Kanao et al., 2015).
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Appendices
Appendix A: Purification of Ubiquitination Enzymes
hUba1 Purification
hUba1 purification followed the procedure outlined in Methods. As a ubiquitination
enzyme, small quantities are needed, so doing a large scale (2 litre culture) purification can
produce enough to ubiquitinate < 100 mg of PCNA.

Figure A1 SDS-PAGE gel outlining Ni-affinity and anion exchange steps in Uba1
purification. Strong contaminants remain.
Purity is not crucial for this protein, but it is still unacceptable at this stage. Protein
was concentrated to 1mL and run on S200 to clean it up.
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Figure A2 Final S200 fractions of Uba1. Acceptable purity has been achieved at this stage.
Peak fractions containing Uba1 were pooled and concentrated to 3.8 mg/mL (32
µM). The protein was distributed in 30 µL aliquots, flash frozen, and stored at -80 ºC until
used in ubiquitination reactions.
hUbC S22R Purification
hUbc S22R purification followed the procedure outlined in Methods. As a
ubiquitination enzyme, small quantities are needed, so doing a large scale (2 litre culture)
purification can produce enough to last a long time. The purification only requires two Ni
columns, one after lysis and one after tag cleavage.
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Figure A3 SDS-PAGE gel demonstrating the purification of UbC. High purity is achieved
after the second Ni-affinity step that follows tag cleavage.
Since the protein is to be frozen and then only used in small quantities for a single
preparative reaction, the small amount of Ni which leached from the column is acceptable.
FT2 and FT3 were pooled and concentrated to 17 mg/mL (1 mM) with a yield of 51 mg.
The concentrated protein was distributed into 200 µL aliquots and frozen down for later
use.
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